Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

2016/09/14 by Chris de Graaf, Dan Donnelly, Denise Wootten +14 · 3 citations
Medicine · #Diabetes Treatment and Management #Pancreatic function and diabetes #Neuroendocrine Tumor Research Advances

paper · pdf · doi:10.1124/pr.115.011395

Citations

• Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes
• Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery
• Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening
• Evolving Concepts in G Protein-Coupled Receptor Endocytosis: The Role in Receptor Desensitization and Signaling

Cited by

• GLP-1 Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives
• GLP-1, Pancreatic β-Cells, and Insulin Secretion: What We Know and Where We Need to Go
• Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations